文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

手术与监测治疗分化良好、无功能性胰腺神经内分泌肿瘤:国家癌症数据库 11 年分析。

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

机构信息

Department of Hematology/Oncology, Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

Department of Medicine, Roswell Park Comprehensive Cancer, University of Buffalo, Buffalo, New York, USA.

出版信息

Oncologist. 2020 Feb;25(2):e276-e283. doi: 10.1634/theoncologist.2019-0466. Epub 2019 Oct 2.


DOI:10.1634/theoncologist.2019-0466
PMID:32043766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7011621/
Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (panNETs) are a rare group of tumors that make up 2%-3% of pancreatic tumors. Recommended treatment for panNETs generally consists of resection for symptomatic or large asymptomatic tumors; however, optimal management for localized disease is still controversial, with conflicting recommendations in established guidelines. Our study aim is to compare surgical intervention versus active surveillance in nonmetastatic panNETs by size of primary tumor. MATERIALS AND METHODS: Using the National Cancer Database, we identified 2,004 patients diagnosed with localized well-differentiated, nonfunctional panNETs (NF-panNETs) between 2004 and 2015. Patients' clinicopathologic characteristics, treatment modalities, and overall survival (OS) were analyzed using frequency statistics, chi-square, and Kaplan-Meier curves. The objective of the study is to assess the outcome of surgical resection versus nonoperative management in patients with panNETs with different tumor sizes. RESULTS: Tumor sizes were divided into three categories: <1 cm, 1-2 cm, and >2 cm. The number of patients with tumor size <1 cm, 1-2 cm, and >2 cm was 220 (11%), 794 (39.6%), and 990 (49.4%), respectively. Overall, 1,781 underwent surgical resection, whereas 223 patients did not. Median follow-up was 25.9 months. After adjusting for covariates, surgical resection was associated with improved OS in patients with tumor size 1-2 cm (hazard ratio [HR] = 0.37) and >2c m (HR = 0.30) but not <1 cm (HR = 2.81). Independent prognostic factors were age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. Higher tumor grade was not associated with worse OS. CONCLUSION: Our findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Intermediate-grade tumors did not result in worse survival outcome compared with low-grade tumors. Future studies might consider prospective randomized clinical trials to validate our findings. IMPLICATIONS FOR PRACTICE: The present study seeks to address the discrepancy in treatment recommendations in the management of nonfunctional pancreatic neuroendocrine tumors (NF-panNETs) by evaluating whether surgical resection is associated with improved overall survival in different tumor size groups as well as elucidating independent prognostic factors in patients with NF-panNETs. Data from the National Cancer Database were reviewed. This study's findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Independent prognostic factors include age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. These findings will help guide medical and surgical oncologists when formulating treatment plans for patients with small NF-panNETs.

摘要

背景:胰腺神经内分泌肿瘤(panNETs)是一种罕见的肿瘤,占胰腺肿瘤的 2%-3%。panNETs 的推荐治疗方法一般包括对有症状或大的无症状肿瘤进行切除术;然而,局部疾病的最佳治疗方法仍存在争议,既定指南中的建议相互矛盾。我们的研究目的是按原发肿瘤大小比较非转移性 panNETs 中的手术干预与主动监测。

材料和方法:利用国家癌症数据库,我们确定了 2004 年至 2015 年间 2004 例局部分化良好、无功能的 panNETs(NF-panNETs)患者。使用频率统计、卡方检验和 Kaplan-Meier 曲线分析患者的临床病理特征、治疗方式和总生存期(OS)。本研究的目的是评估不同肿瘤大小的 panNETs 患者手术切除与非手术治疗的结果。

结果:肿瘤大小分为三类:<1cm、1-2cm 和>2cm。肿瘤大小<1cm、1-2cm 和>2cm 的患者数量分别为 220 例(11%)、794 例(39.6%)和 990 例(49.4%)。总体而言,1781 例患者接受了手术切除,223 例患者未接受。中位随访时间为 25.9 个月。在调整了混杂因素后,手术切除与肿瘤大小为 1-2cm(风险比[HR] = 0.37)和>2cm(HR = 0.30)的患者的 OS 改善相关,但与肿瘤大小<1cm 的患者(HR = 2.81)无关。独立的预后因素包括诊断时的年龄、Charlson-Deyo 合并症评分、分期、肿瘤位置和手术切除。较高的肿瘤分级与较差的 OS 无关。

结论:我们的研究结果表明,主动监测对于<1cm 的 NF-panNETs 可能是一种安全的方法。较大的肿瘤可能需要积极干预。中等级别的肿瘤与低级别肿瘤相比,并未导致生存结果更差。未来的研究可能会考虑前瞻性随机临床试验来验证我们的发现。

临床意义:本研究旨在通过评估手术切除与不同肿瘤大小组患者的总生存期改善是否相关,以及阐明 NF-panNETs 患者的独立预后因素,解决非功能性胰腺神经内分泌肿瘤(NF-panNETs)治疗建议不一致的问题。对国家癌症数据库的数据进行了回顾。本研究结果表明,主动监测对于<1cm 的 NF-panNETs 可能是一种安全的方法。较大的肿瘤可能需要积极干预。独立的预后因素包括诊断时的年龄、Charlson-Deyo 合并症评分、分期、肿瘤位置和手术切除。这些发现将有助于指导医疗和外科肿瘤医生为小 NF-panNETs 患者制定治疗计划。

相似文献

[1]
Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Oncologist. 2020-2

[2]
Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.

JAMA Netw Open. 2023-3-1

[3]
Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.

Front Endocrinol (Lausanne). 2022

[4]
Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?

Surgery. 2019-9-16

[5]
A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.

Ann Surg. 2019-9

[6]
Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

J Gastrointest Surg. 2017-5

[7]
Does Prior Cancer Have an Influence on the Survival Outcomes of Patients with Localized Pancreatic Neuroendocrine Tumors?

Chin Med Sci J. 2021-12-31

[8]
Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?

J Surg Oncol. 2019-10-16

[9]
Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.

Ann Surg Oncol. 2017-10-27

[10]
Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.

World J Surg Oncol. 2019-4-11

引用本文的文献

[1]
Surgical Versus Nonsurgical Management of Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Ann Surg Oncol. 2025-7-24

[2]
Surgical vs. Conservative Management of Patients with Nonfunctioning Pancreatic Neuroendocrine Tumors Smaller than 2 cm (NF-PANNETs < 2 cm) Systematic Review and Meta-Analysis.

Cancers (Basel). 2025-5-13

[3]
The Landmark Series: Surgical Management of Functioning and Non-Functioning Pancreatic Neuroendocrine Tumors.

Ann Surg Oncol. 2025-5-3

[4]
Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.

Curr Oncol Rep. 2025-2

[5]
NET guidelines for white patients may not fit Asian patients.

Am J Surg. 2025-2

[6]
Somatostatin Analogs Versus Active Surveillance in Small Pancreatic Neuroendocrine Tumors.

Pancreas. 2025-7-1

[7]
Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.

J Surg Res. 2024-10

[8]
Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features.

Eur Radiol. 2024-12

[9]
Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.

Cancers (Basel). 2024-4-14

[10]
Race and Odds of Surgery Offer in Small Bowel and Pancreas Neuroendocrine Neoplasms.

Ann Surg Oncol. 2024-5

本文引用的文献

[1]
Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review.

Pancreatology. 2019-2-18

[2]
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

J Natl Compr Canc Netw. 2018-6

[3]
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Endocr Relat Cancer. 2018-3

[4]
Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis.

HPB (Oxford). 2017-4

[5]
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.

Neuroendocrinology. 2017

[6]
Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.

Br J Surg. 2016-10-5

[7]
A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.

Oncotarget. 2016-4-5

[8]
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Neuroendocrinology. 2016

[9]
Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

World J Surg. 2016-3

[10]
Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Ann Surg Oncol. 2016-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索